Yubin Kang MD
Hematologic Oncology
Professor, Medicine, Duke University Medical Center
Join to View Full Profile
800 NE 10th StSte BOklahoma City, OK 73104
Phone+1 405-271-4022
Fax+1 405-271-3020
Dr. Kang is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Iowa Health Care Medical CenterResidency, Internal Medicine, 2005 - 2007
St Luke's HospitalInternship, Internal Medicine, 2004 - 2005- The Second Military Medicine UnivClass of 1985
Certifications & Licensure
SC State Medical License 2010 - 2027
NC State Medical License 2007 - 2026
OK State Medical License 2025 - 2026
IA State Medical License 2005 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Start of enrollment: 2011 Dec 01
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma Start of enrollment: 2011 Aug 01
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation Start of enrollment: 2012 May 01
Publications & Presentations
PubMed
- Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.Allison O Taylor, Joshua S Mercer, Claire I Bradbury, Samantha M Thomas, Edwin Alyea 3rd
Bone Marrow Transplantation. 2026-06-01 - Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.Amber Feng, Jian Wu, Taewoong Choi, Xiaobei Wang, Tanya Bellavia
Transplantation and Cellular Therapy. 2026-05-01 - Vitamin D Deficiency and Efficacy of Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation.Hilary M Winthrop, Yan Li, Delaney Underwood, Lauren Hill, Alessandro Racioppi
Transplantation and Cellular Therapy. 2026-05-01
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
RedHill Biopharma Announces Presentation on YELIVA® (Opaganib) for Multiple Myeloma at EORTC-NCI-AACR SymposiumNovember 14th, 2018
Grant Support
- Thioredoxin derivatives for radiation mitigationUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2025–2030
- Role of SLAMF7 in Racial Disparities in MyelomaDUKE UNIVERSITY2023–2025
- Enhancing CAR T therapy in multiple myelomaDUKE UNIVERSITY2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
